vs

Side-by-side financial comparison of INSEEGO CORP. (INSG) and RIGEL PHARMACEUTICALS INC (RIGL). Click either name above to swap in a different company.

RIGEL PHARMACEUTICALS INC is the larger business by last-quarter revenue ($69.8M vs $48.4M, roughly 1.4× INSEEGO CORP.). RIGEL PHARMACEUTICALS INC runs the higher net margin — 384.0% vs 1.0%, a 383.1% gap on every dollar of revenue. On growth, RIGEL PHARMACEUTICALS INC posted the faster year-over-year revenue change (21.2% vs 0.6%). Over the past eight quarters, RIGEL PHARMACEUTICALS INC's revenue compounded faster (53.7% CAGR vs 13.6%).

Inseego Corp designs, manufactures and delivers advanced 5G and IoT solutions including mobile hotspots, edge computing devices, and cloud-based device management platforms. It primarily serves telecom operators, enterprise clients, and public sector customers across global markets.

Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing targeted small molecule therapies for autoimmune, inflammatory, and hematologic diseases. Its approved flagship product treats adult immune thrombocytopenia, with primary operations and core markets in the United States, addressing unmet medical needs for underserved patient groups.

INSG vs RIGL — Head-to-Head

Bigger by revenue
RIGL
RIGL
1.4× larger
RIGL
$69.8M
$48.4M
INSG
Growing faster (revenue YoY)
RIGL
RIGL
+20.5% gap
RIGL
21.2%
0.6%
INSG
Higher net margin
RIGL
RIGL
383.1% more per $
RIGL
384.0%
1.0%
INSG
Faster 2-yr revenue CAGR
RIGL
RIGL
Annualised
RIGL
53.7%
13.6%
INSG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
INSG
INSG
RIGL
RIGL
Revenue
$48.4M
$69.8M
Net Profit
$469.0K
$268.1M
Gross Margin
42.2%
91.5%
Operating Margin
2.7%
33.2%
Net Margin
1.0%
384.0%
Revenue YoY
0.6%
21.2%
Net Profit YoY
182.9%
1769.2%
EPS (diluted)
$-0.02
$14.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
INSG
INSG
RIGL
RIGL
Q4 25
$48.4M
$69.8M
Q3 25
$45.9M
$69.5M
Q2 25
$40.2M
$101.7M
Q1 25
$31.7M
$53.3M
Q4 24
$48.1M
$57.6M
Q3 24
$54.0M
$55.3M
Q2 24
$51.6M
$36.8M
Q1 24
$37.5M
$29.5M
Net Profit
INSG
INSG
RIGL
RIGL
Q4 25
$469.0K
$268.1M
Q3 25
$1.4M
$27.9M
Q2 25
$507.0K
$59.6M
Q1 25
$-1.6M
$11.4M
Q4 24
$-566.0K
$14.3M
Q3 24
$9.0M
$12.4M
Q2 24
$624.0K
$-1.0M
Q1 24
$-4.5M
$-8.2M
Gross Margin
INSG
INSG
RIGL
RIGL
Q4 25
42.2%
91.5%
Q3 25
41.6%
93.2%
Q2 25
41.1%
95.6%
Q1 25
47.3%
91.7%
Q4 24
37.3%
89.9%
Q3 24
34.8%
85.5%
Q2 24
36.4%
92.4%
Q1 24
35.3%
93.1%
Operating Margin
INSG
INSG
RIGL
RIGL
Q4 25
2.7%
33.2%
Q3 25
4.7%
40.9%
Q2 25
3.2%
60.1%
Q1 25
-1.3%
23.9%
Q4 24
3.7%
28.9%
Q3 24
1.9%
25.4%
Q2 24
3.6%
1.2%
Q1 24
-7.9%
-23.6%
Net Margin
INSG
INSG
RIGL
RIGL
Q4 25
1.0%
384.0%
Q3 25
3.1%
40.2%
Q2 25
1.3%
58.6%
Q1 25
-5.0%
21.5%
Q4 24
-1.2%
24.9%
Q3 24
16.6%
22.5%
Q2 24
1.2%
-2.8%
Q1 24
-11.9%
-27.9%
EPS (diluted)
INSG
INSG
RIGL
RIGL
Q4 25
$-0.02
$14.11
Q3 25
$0.03
$1.46
Q2 25
$-0.03
$3.28
Q1 25
$-0.16
$0.63
Q4 24
$0.62
$0.82
Q3 24
$-0.06
$0.70
Q2 24
$-0.02
$-0.06
Q1 24
$-0.44
$-0.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
INSG
INSG
RIGL
RIGL
Cash + ST InvestmentsLiquidity on hand
$24.9M
$155.0M
Total DebtLower is stronger
$52.5M
Stockholders' EquityBook value
$-4.0M
$391.5M
Total Assets
$93.8M
$513.6M
Debt / EquityLower = less leverage
0.13×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
INSG
INSG
RIGL
RIGL
Q4 25
$24.9M
$155.0M
Q3 25
$14.6M
$137.1M
Q2 25
$13.2M
$108.4M
Q1 25
$35.1M
$77.1M
Q4 24
$39.6M
$77.3M
Q3 24
$12.0M
$61.1M
Q2 24
$49.0M
$49.1M
Q1 24
$12.3M
$49.5M
Total Debt
INSG
INSG
RIGL
RIGL
Q4 25
$52.5M
Q3 25
$60.0M
Q2 25
$60.0M
Q1 25
$60.0M
Q4 24
$60.0M
Q3 24
$60.0M
Q2 24
$60.0M
Q1 24
$60.0M
Stockholders' Equity
INSG
INSG
RIGL
RIGL
Q4 25
$-4.0M
$391.5M
Q3 25
$-7.7M
$117.6M
Q2 25
$-10.5M
$81.9M
Q1 25
$-13.0M
$18.6M
Q4 24
$-12.9M
$3.3M
Q3 24
$-85.1M
$-14.6M
Q2 24
$-101.8M
$-29.9M
Q1 24
$-105.6M
$-31.7M
Total Assets
INSG
INSG
RIGL
RIGL
Q4 25
$93.8M
$513.6M
Q3 25
$85.8M
$242.5M
Q2 25
$83.1M
$206.7M
Q1 25
$93.0M
$176.0M
Q4 24
$100.0M
$164.0M
Q3 24
$113.4M
$139.4M
Q2 24
$149.6M
$128.4M
Q1 24
$122.1M
$126.5M
Debt / Equity
INSG
INSG
RIGL
RIGL
Q4 25
0.13×
Q3 25
0.51×
Q2 25
0.73×
Q1 25
3.23×
Q4 24
18.25×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
INSG
INSG
RIGL
RIGL
Operating Cash FlowLast quarter
$12.0M
$22.0M
Free Cash FlowOCF − Capex
$11.6M
FCF MarginFCF / Revenue
24.0%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
25.50×
0.08×
TTM Free Cash FlowTrailing 4 quarters
$6.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
INSG
INSG
RIGL
RIGL
Q4 25
$12.0M
$22.0M
Q3 25
$3.2M
$24.0M
Q2 25
$-4.5M
$30.5M
Q1 25
$-3.5M
$-893.0K
Q4 24
$-14.2M
$14.5M
Q3 24
$14.8M
$21.7M
Q2 24
$27.6M
$302.0K
Q1 24
$5.2M
$-5.0M
Free Cash Flow
INSG
INSG
RIGL
RIGL
Q4 25
$11.6M
Q3 25
$3.1M
Q2 25
$-4.7M
Q1 25
$-3.5M
Q4 24
$-14.3M
Q3 24
$14.8M
Q2 24
$27.6M
Q1 24
FCF Margin
INSG
INSG
RIGL
RIGL
Q4 25
24.0%
Q3 25
6.7%
Q2 25
-11.6%
Q1 25
-11.0%
Q4 24
-29.7%
Q3 24
27.4%
Q2 24
53.5%
Q1 24
Capex Intensity
INSG
INSG
RIGL
RIGL
Q4 25
0.7%
Q3 25
0.2%
Q2 25
0.5%
Q1 25
0.1%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
INSG
INSG
RIGL
RIGL
Q4 25
25.50×
0.08×
Q3 25
2.22×
0.86×
Q2 25
-8.81×
0.51×
Q1 25
-0.08×
Q4 24
1.01×
Q3 24
1.65×
1.75×
Q2 24
44.31×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons